Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1226

1.

Availability of Grocery Delivery to Food Deserts in States Participating in the Online Purchase Pilot.

Brandt EJ, Silvestri DM, Mande JR, Holland ML, Ross JS.

JAMA Netw Open. 2019 Dec 2;2(12):e1916444. doi: 10.1001/jamanetworkopen.2019.16444. No abstract available.

PMID:
31790562
2.

Digital medicine systems: an evergreening strategy or an advance in medication management?

Egilman AC, Ross JS.

BMJ Evid Based Med. 2019 Dec;24(6):203-204. doi: 10.1136/bmjebm-2019-111265. No abstract available.

PMID:
31754072
3.

Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.

Brennan JM, Wruck L, Pencina MJ, Clare RM, Lopes RD, Alexander JH, O'Brien S, Krucoff M, Rao SV, Wang TY, Curtis LH, Newby LK, Granger CB, Patel M, Mahaffey K, Ross JS, Normand SL, Eloff BC, Caños DA, Lokhnygina YV, Roe MT, Califf RM, Marinac-Dabic D, Peterson ED.

Am Heart J. 2019 Dec;218:110-122. doi: 10.1016/j.ahj.2019.09.002. Epub 2019 Sep 12.

PMID:
31726314
4.

The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement.

Kent DM, Paulus JK, van Klaveren D, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW.

Ann Intern Med. 2019 Nov 12. doi: 10.7326/M18-3667. [Epub ahead of print]

PMID:
31711134
5.

The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Kent DM, van Klaveren D, Paulus JK, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW.

Ann Intern Med. 2019 Nov 12. doi: 10.7326/M18-3668. [Epub ahead of print]

PMID:
31711094
6.

Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews.

Liu P, Ross JS, Ioannidis JP, Dhruva SS, Vasiliou V, Wallach JD.

Clin Trials. 2019 Nov 10:1740774519887148. doi: 10.1177/1740774519887148. [Epub ahead of print] No abstract available.

PMID:
31709809
7.

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F.

Eur Urol. 2019 Nov 8. pii: S0302-2838(19)30825-5. doi: 10.1016/j.eururo.2019.10.026. [Epub ahead of print]

PMID:
31708296
8.

Accidental drug overdose deaths in Connecticut, 2012-2018: The rise of polysubstance detection?

Rhee TG, Ross JS, Rosenheck RA, Grau LE, Fiellin DA, Becker WC.

Drug Alcohol Depend. 2019 Dec 1;205:107671. doi: 10.1016/j.drugalcdep.2019.107671. Epub 2019 Oct 25.

PMID:
31706248
9.

Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.

Solotke MT, Ross JS, Shah ND, Karaca-Mandic P, Dhruva SS.

J Manag Care Spec Pharm. 2019 Nov;25(11):1201-1217. doi: 10.18553/jmcp.2019.25.11.1201.

10.

The Human Costs of Medicare Fraud and Abuse.

Ross JS.

JAMA Intern Med. 2019 Oct 28. doi: 10.1001/jamainternmed.2019.5004. [Epub ahead of print] No abstract available.

PMID:
31657845
11.

Confidentiality Orders and Public Interest in Drug and Medical Device Litigation.

Egilman AC, Kesselheim AS, Krumholz HM, Ross JS, Kim J, Kapczynski A.

JAMA Intern Med. 2019 Oct 28:1-8. doi: 10.1001/jamainternmed.2019.5161. [Epub ahead of print]

PMID:
31657836
12.

Modernizing the FDA's 510(k) Pathway.

Rathi VK, Ross JS.

N Engl J Med. 2019 Nov 14;381(20):1891-1893. doi: 10.1056/NEJMp1908654. Epub 2019 Oct 23. No abstract available.

PMID:
31644865
13.

Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study.

Liu P, Ioannidis JPA, Ross JS, Dhruva SS, Luxkaranayagam AT, Vasiliou V, Wallach JD.

BMC Med. 2019 Oct 21;17(1):188. doi: 10.1186/s12916-019-1420-8.

14.

Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics.

Vijay A, Gupta R, Liu P, Dhruva SS, Shah ND, Ross JS.

J Gen Intern Med. 2019 Oct 17. doi: 10.1007/s11606-019-05432-6. [Epub ahead of print] No abstract available.

PMID:
31625043
15.

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.

Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.

Oncologist. 2019 Oct 16. pii: theoncologist.2019-0603. doi: 10.1634/theoncologist.2019-0603. [Epub ahead of print] Review.

PMID:
31619547
16.

Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016.

Kahn PA, Dhruva SS, Rhee TG, Ross JS.

JAMA Netw Open. 2019 Oct 2;2(10):e1913298. doi: 10.1001/jamanetworkopen.2019.13298.

17.

Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing.

Mikubo M, Seto K, Kitamura A, Nakaguro M, Hattori Y, Maeda N, Miyazaki T, Watanabe K, Murakami H, Tsukamoto T, Yamada T, Fujita S, Masago K, Ramkissoon S, Ross JS, Elvin J, Yatabe Y.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33409-4. doi: 10.1016/j.jtho.2019.09.081. [Epub ahead of print]

PMID:
31605798
18.

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM.

Oncologist. 2019 Oct 11. pii: theoncologist.2018-0528. doi: 10.1634/theoncologist.2018-0528. [Epub ahead of print]

PMID:
31604903
19.

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.

Jiao K, Gupta R, Fox E, Kesselheim A, Ross JS.

JAMA Netw Open. 2019 Oct 2;2(10):e1913029. doi: 10.1001/jamanetworkopen.2019.13029. No abstract available.

20.

Home Health Care After Skilled Nursing Facility Discharge Following Heart Failure Hospitalization.

Weerahandi H, Bao H, Herrin J, Dharmarajan K, Ross JS, Jones S, Horwitz LI.

J Am Geriatr Soc. 2019 Oct 11. doi: 10.1111/jgs.16179. [Epub ahead of print]

PMID:
31603248
21.

Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.

Li G, Pavlick D, Chung JH, Bauer T, Tan BA, Peguero J, Ward P, Kallab A, Bufill J, Hoffman A, Sadiq A, Edenfield J, He J, Cooke M, Hughes J, Forcier B, Nahas M, Stephens P, Ali SM, Schrock AB, Ross JS, Miller VA, Gregg JP.

J Gastrointest Oncol. 2019 Oct;10(5):831-840. doi: 10.21037/jgo.2019.05.05.

22.

Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence.

Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS.

JAMA Netw Open. 2019 Oct 2;2(10):e1912869. doi: 10.1001/jamanetworkopen.2019.12869.

23.

Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates.

Dayoub EJ, Ross JS, Shah ND, Dhruva SS.

Circulation. 2019 Oct;140(14):1227-1230. doi: 10.1161/CIRCULATIONAHA.119.040580. Epub 2019 Sep 30. No abstract available.

PMID:
31567008
24.

Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10-Year Assessment.

DuBose-Briski V, Yao X, Dunlay SM, Dhruva SS, Ross JS, Shah ND, Noseworthy PA.

J Am Heart Assoc. 2019 Oct;8(19):e012065. doi: 10.1161/JAHA.119.012065. Epub 2019 Sep 28.

25.

Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.

Zhang AD, Ross JS.

J Law Med Ethics. 2019 Sep;47(3):393-395. doi: 10.1177/1073110519876170.

PMID:
31560627
26.

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha P, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LG.

J Clin Invest. 2019 Oct 1;129(10):4276-4289. doi: 10.1172/JCI128227.

27.

Evidence Supporting US Food and Drug Administration Drug Safety Communications.

Ross JS.

JAMA Intern Med. 2019 Sep 3. doi: 10.1001/jamainternmed.2019.3065. [Epub ahead of print] No abstract available.

PMID:
31479098
28.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA, Ross JS, Hartmaier RJ, Huang SA, Sun JX.

J Mol Diagn. 2019 Nov;21(6):1053-1066. doi: 10.1016/j.jmoldx.2019.06.011. Epub 2019 Aug 22.

29.

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients.

Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE.

Nat Commun. 2019 Aug 19;10(1):3722. doi: 10.1038/s41467-019-11530-0.

30.

Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.

McCoy RG, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah ND.

Diabetes Technol Ther. 2019 Dec;21(12):702-712. doi: 10.1089/dia.2019.0213. Epub 2019 Oct 9.

PMID:
31418588
31.

Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.

Yakirevich E, Madison R, Fridman E, Mangray S, Carneiro BA, Lu S, Cooke M, Bratslavsky G, Webster J, Ross JS, Ali SM.

Eur Urol Oncol. 2019 Apr 22. pii: S2588-9311(19)30044-6. doi: 10.1016/j.euo.2019.04.002. [Epub ahead of print]

PMID:
31412008
32.

Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.

Egilman AC, Zhang AD, Wallach JD, Ross JS.

Ann Intern Med. 2019 Aug 13. doi: 10.7326/M19-1085. [Epub ahead of print] No abstract available.

PMID:
31404926
33.

MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

Chu LP, Franck D, Parachoniak CA, Gregg JP, Moore MG, Farwell DG, Rao S, Heilmann AM, Erlich RL, Ross JS, Miller VA, Ali S, Riess JW.

Oncologist. 2019 Oct;24(10):1305-1308. doi: 10.1634/theoncologist.2019-0230. Epub 2019 Aug 7.

PMID:
31391294
34.

Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016.

Jeffery MM, Hooten WM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P.

JAMA Netw Open. 2019 Aug 2;2(8):e198325. doi: 10.1001/jamanetworkopen.2019.8325.

35.

Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell Tumors.

Necchi A, Ross JS, Spiess PE.

J Clin Oncol. 2019 Sep 10;37(26):2314-2316. doi: 10.1200/JCO.19.01672. Epub 2019 Jul 30. No abstract available.

PMID:
31361537
36.

Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.

Egilman AC, Wallach JD, Dhruva SS, Gonsalves GS, Ross JS.

J Gen Intern Med. 2019 Nov;34(11):2319-2321. doi: 10.1007/s11606-019-05149-6. No abstract available.

PMID:
31313117
37.

The Bleeding Edge: Documenting Innovation and Injury in the Medical Device Industry.

Pendyal A, Ross JS.

JAMA. 2019 Jul 16;322(3):190-192. doi: 10.1001/jama.2019.8147. No abstract available.

PMID:
31310276
38.

Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015.

Zhang AD, Schwartz JL, Ross JS.

Milbank Q. 2019 Sep;97(3):796-819. doi: 10.1111/1468-0009.12403. Epub 2019 Jul 14.

PMID:
31304643
39.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Sokol ES, Pavlick D, Frampton GM, Ross JS, Miller VA, Ali SM, Lotan TL, Pardoll DM, Chung JH, Antonarakis ES.

Oncologist. 2019 Dec;24(12):1526-1533. doi: 10.1634/theoncologist.2019-0214. Epub 2019 Jul 10.

PMID:
31292271
41.

Clinical Trial Evidence for the Real World.

Ross JS, Covinsky K.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1500. [Epub ahead of print] No abstract available.

PMID:
31282933
42.

Association Between Industry Payments to Physicians and Gabapentinoid Prescribing.

Rhee TG, Ross JS.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1082. [Epub ahead of print] No abstract available.

PMID:
31282922
43.

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.

Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ.

Oncotarget. 2019 Jun 18;10(40):4018-4025. doi: 10.18632/oncotarget.26998. eCollection 2019 Jun 18.

44.

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J.

Oncologist. 2019 Nov;24(11):1462-1468. doi: 10.1634/theoncologist.2019-0121. Epub 2019 Jun 27.

PMID:
31249137
45.

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W.

J Thorac Oncol. 2019 Oct;14(10):1807-1817. doi: 10.1016/j.jtho.2019.06.016. Epub 2019 Jun 22.

PMID:
31238177
46.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

47.

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.

Wallach JD, Luxkaranayagam AT, Dhruva SS, Miller JE, Ross JS.

BMC Med. 2019 Jun 17;17(1):117. doi: 10.1186/s12916-019-1344-3.

48.

SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.

Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA.

Mod Pathol. 2019 Nov;32(11):1675-1687. doi: 10.1038/s41379-019-0303-z. Epub 2019 Jun 12.

PMID:
31190001
49.

Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals.

Bikdeli B, Welsh JW, Akram Y, Punnanithinont N, Lee I, Desai NR, Kaul S, Stone GW, Ross JS, Krumholz HM.

Circulation. 2019 Jul 30;140(5):379-389. doi: 10.1161/CIRCULATIONAHA.119.040214. Epub 2019 Jun 10.

PMID:
31177811
50.

Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.

Necchi A, Bratslavsky G, Shapiro O, Elvin JA, Vergilio JA, Killian JK, Ngo N, Ramkissoon S, Severson E, Hemmerich AC, Ali SM, Chung JH, Reddy P, Miller VA, Schrock AB, Gay LM, Ross JS, Jacob JM.

Eur Urol Focus. 2019 Sep;5(5):748-755. doi: 10.1016/j.euf.2019.05.012. Epub 2019 May 27.

PMID:
31147264

Supplemental Content

Support Center